The COVID-19 virus is mutating rapidly. As subvariants like BA.4 and BA.5 emerge, we must act fast to curb the pandemic. Vaccination is the most effective way to control epidemic, but the protection it offers declines as the virus evolves. Predicting vaccine effectiveness in a short time frame is key to winning this battle. CUHK researchers have developed a bioinformatics platform that can provide a snapshot of vaccine effectiveness in real time, instead of it taking months.
The Microbiota I-Centre of CUHK has identified distinct gut microbiome profiles that can characterise “long COVID”. This is the world’s first study to demonstrate gut microbiota as a key determinant of long COVID. These distinct gut microbial signatures can be used as a diagnostic tool and to guide therapy.
A new pathway has been found whereby SARS-CoV-2 infects the endothelium cells – the innermost layer of the blood vessels, causing hyper inflammation, blood clotting and thrombosis in severe COVID-19 patients. In a collaborative research, a CU Medicine team has discovered that the virus induces inflammation by activating a unique cell surface receptor called (TLR) 4, without entering the host cell.
People who have recovered from a COVID-19 infection may suffer from poor memory, hair loss, difficulty in sleeping and other long-term consequences, which are commonly known as “long COVID”. CU Medicine has found that patients with long COVID have a less diverse gut microbiome, indicating that gut microbiome composition may be linked to the risk of developing long COVID, while gut microbiota modulation could facilitate timely recovery and reduce the burden of post-acute COVID-19 syndrome.
Sinovac and BioNTech work more effectively in people who have an abundance amount of a particular bacterium called Bifidobacterium adolescentis in their gut. In most of us, this reduces with age, modern diet, stress, and the use of antibiotics, and a joint CUHK-HKU study has found that those who lack it have a lower antibody response to the vaccines. This implies that modulating the gut has potential to power up the impact of COVID vaccines.
Simeprevir was a successful drug retired from the fight against the hepatitis C virus when new drugs and advanced treatment came into the field in recent years. An international research team led by CUHK and HKU seeking an effective drug molecule against COVID-19 has re-enlisted simeprevir as a potent treatment to suppress the replication of SARS-CoV-2.
Apart from achieving research excellence, the education sector has the prime responsibility to lookout for the interests of the community in these challenging times. CUHK rolled out thorough infection control measures and vigorous vaccination promotion efforts in fighting against COVID-19 , to get everyone back to their normal lives as soon as possible.
Research results show that physical distancing can only be relaxed in ratio to the rate of vaccination in the city’s population until herd immunity is achieved. A CUHK team developed a social contact index (SCI) which quantifies the effect of distancing and vaccination combined, to bridge gaps between intervention measures and disease transmission.
Scared kids gagging on swabs probing into noses and throats or embarrassed old folk trying to heave up saliva has been the unhappy side of COVID-19 testing. Now, a nasal strip sampling for COVID-19 test that is gentle, fast, easy and accurate is on its way for all ages, equaling one of the standard test methods and out-performing the other.
Not only old age and other chronic conditions let in COVID-19. Those with liver damage are revealed as vulnerable and face eight times the risk of experiencing intensive care, mechanical ventilation, or death. CU Medicine researchers led an international hepatologists group in a statement pushing for better clinical management of COVID-19 liver disease sufferers.